Parnassus Investments CA lifted its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 62.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,115,000 shares of the medical instruments supplier’s stock after purchasing an additional 815,000 shares during the quarter. Parnassus Investments CA owned approximately 0.92% of DENTSPLY SIRONA worth $126,498,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of DENTSPLY SIRONA by 2.5% during the 2nd quarter. Vanguard Group Inc. now owns 22,728,062 shares of the medical instruments supplier’s stock worth $1,473,688,000 after purchasing an additional 562,993 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of DENTSPLY SIRONA by 22.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,474,432 shares of the medical instruments supplier’s stock worth $419,802,000 after purchasing an additional 1,181,547 shares during the last quarter. Veritas Asset Management LLP increased its stake in shares of DENTSPLY SIRONA by 2.6% during the 2nd quarter. Veritas Asset Management LLP now owns 6,201,155 shares of the medical instruments supplier’s stock worth $402,083,000 after purchasing an additional 157,616 shares during the last quarter. Epoch Investment Partners Inc. increased its stake in shares of DENTSPLY SIRONA by 3.5% during the 2nd quarter. Epoch Investment Partners Inc. now owns 3,686,004 shares of the medical instruments supplier’s stock worth $239,001,000 after purchasing an additional 123,668 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of DENTSPLY SIRONA by 15.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,831,951 shares of the medical instruments supplier’s stock worth $118,783,000 after purchasing an additional 240,740 shares during the last quarter. Institutional investors own 93.71% of the company’s stock.

Several brokerages have recently commented on XRAY. Barrington Research upgraded shares of DENTSPLY SIRONA from a “market perform” rating to an “outperform” rating and set a $73.00 price target on the stock in a research note on Monday. Zacks Investment Research lowered shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Monday, October 30th. Robert W. Baird set a $63.00 price target on shares of DENTSPLY SIRONA and gave the stock a “buy” rating in a research note on Thursday, October 19th. Stifel Nicolaus restated a “buy” rating on shares of DENTSPLY SIRONA in a research note on Thursday, October 19th. Finally, Morgan Stanley restated an “overweight” rating and set a $69.00 price target (up previously from $67.00) on shares of DENTSPLY SIRONA in a research note on Friday, October 6th. Three analysts have rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $66.60.

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) traded down $1.06 during trading hours on Monday, reaching $63.74. 799,893 shares of the company were exchanged, compared to its average volume of 1,992,630. DENTSPLY SIRONA Inc. has a 1-year low of $52.53 and a 1-year high of $66.00. The company has a quick ratio of 1.59, a current ratio of 2.32 and a debt-to-equity ratio of 0.21. The firm has a market cap of $14,871.72, a price-to-earnings ratio of 25.82, a PEG ratio of 2.66 and a beta of 1.27.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.04. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $978.99 million. During the same period last year, the business posted $0.66 EPS. DENTSPLY SIRONA’s revenue was up 5.8% compared to the same quarter last year. equities analysts anticipate that DENTSPLY SIRONA Inc. will post 2.67 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Parnassus Investments CA Has $126.50 Million Stake in DENTSPLY SIRONA Inc. (XRAY)” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/parnassus-investments-ca-has-126-50-million-stake-in-dentsply-sirona-inc-xray/1683223.html.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY).

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.